The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [ 11C]telmisartan

Molecular Pharmaceutics

Volumn 8, Issue 5, 2011, Pages 1789-1798

  Takashima, Tadayuki ^a   Hashizume, Yoshinobu ^a   Katayama, Yumiko ^a   Murai, MacHiko ^a   Wada, Yasuhiro ^a   Maeda, Kazuya ^b   Sugiyama, Yuichi ^b   Watanabe, Yasuyoshi ^a  

^a RIKEN   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

hepatobiliary transport; OATP Oatp (organic anion transporting polypeptide); positron emission tomography (PET); telmisartan

Indexed keywords

ACYLGLUCURONIDE; BIBT 9584; GLUCURONIDE; ORGANIC ANION TRANSPORTER; POLYPEPTIDE; RADIOISOTOPE; RIFAMPICIN; TELMISARTAN; TELMISARTAN C 11; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILE FLOW; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE ANALYSIS; INTESTINE; LIVER; LIVER BLOOD FLOW; LIVER CLEARANCE; MALE; NONHUMAN; PLASMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RAT; TISSUE DISTRIBUTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BILE; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CARBON RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEASIBILITY STUDIES; LIVER; LIVER CIRCULATION; MALE; METABOLIC CLEARANCE RATE; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; POSITRON-EMISSION TOMOGRAPHY; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN; TISSUE DISTRIBUTION;

EID: 80053490330     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200160t     Document Type: Article

References (33)

1. Stangier, J.; Schmid, J.; Turck, D.; Switek, H.; Verhagen, A.; Peeters, P. A.; van Marle, S. P.; Tamminga, W. J.; Sollie, F. A.; Jonkman, J. H. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers J. Clin. Pharmacol. 2000, 40 (12 Part 1) 1312-22
2. Stangier, J.; Su, C. A.; Schondorfer, G.; Roth, W. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers J. Clin. Pharmacol. 2000, 40 (12 Part 1) 1355-64
3. Wienen, W. E., M.; van Meel, J. C. A.; Stangier, J.; Busch, U.; Ebner, T.; Schmid, J.; Lehmann, H.; Matzek, K.; Kempthorne-Rawson, J.; Gladigau, V.; Hauel, N. H. A review on Telmisartan: A Novel, Long-Acting Angiotensin II-Receptor Antagonist Cardiovasc. Drug Rev. 2000, 18 (2) 127-154
4. Nishino, A.; Kato, Y.; Igarashi, T.; Sugiyama, Y. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan Drug Metab. Dispos. 2000, 28 (10) 1146-8
5. Ishiguro, N.; Maeda, K.; Kishimoto, W.; Saito, A.; Harada, A.; Ebner, T.; Roth, W.; Igarashi, T.; Sugiyama, Y. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans Drug Metab. Dispos. 2006, 34 (7) 1109-15
6. Ishiguro, N.; Maeda, K.; Saito, A.; Kishimoto, W.; Matsushima, S.; Ebner, T.; Roth, W.; Igarashi, T.; Sugiyama, Y. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide Drug Metab. Dispos. 2008, 36 (4) 796-805 (Pubitemid 351468387)
7. Hagenbuch, B.; Meier, P. J. The superfamily of organic anion transporting polypeptides Biochim. Biophys. Acta 2003, 1609 (1) 1-18 (Pubitemid 36044060)
8. Vavricka, S. R.; Van Montfoort, J.; Ha, H. R.; Meier, P. J.; Fattinger, K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver Hepatology 2002, 36 (1) 164-72 (Pubitemid 34700774)
9. Hirano, M.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1 Drug Metab. Dispos. 2006, 34 (7) 1229-36
10. Kiyotani, K.; Mushiroda, T.; Kubo, M.; Zembutsu, H.; Sugiyama, Y.; Nakamura, Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia Cancer Sci. 2008, 99 (5) 967-72 (Pubitemid 351997599)
11. Kusuhara, H.; Sugiyama, Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney Drug Metab. Pharmacokinet. 2009, 24 (1) 37-52
12. Watanabe, T.; Maeda, K.; Kondo, T.; Nakayama, H.; Horita, S.; Kusuhara, H.; Sugiyama, Y. Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments Drug Metab. Dispos. 2009, 37 (7) 1471-9
13. Watanabe, T.; Kusuhara, H.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans J. Pharmacol. Exp. Ther. 2009, 328 (2) 652-62
14. Watanabe, T.; Kusuhara, H.; Maeda, K.; Kanamaru, H.; Saito, Y.; Hu, Z.; Sugiyama, Y. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans Drug Metab. Dispos. 2010, 38 (2) 215-22
15. Takashima, T.; Nagata, H.; Nakae, T.; Cui, Y.; Wada, Y.; Kitamura, S.; Doi, H.; Suzuki, M.; Maeda, K.; Kusuhara, H.; Sugiyama, Y.; Watanabe, Y. Positron Emission Tomography Studies Using (15R)-16-m-[11C]tolyl-17,18,19,20- tetranorisocarbacyclin Methyl Ester for the Evaluation of Hepatobiliary Transport J. Pharmacol. Exp. Ther. 2010, 335 (2) 314-23
16. Kim, D. C.; Sugiyama, Y.; Satoh, H.; Fuwa, T.; Iga, T.; Hanano, M. Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues J. Pharm. Sci. 1988, 77 (3) 200-7
17. Ebner, T.; Heinzel, G.; Prox, A.; Beschke, K.; Wachsmuth, H. Disposition and chemical stability of telmisartan 1-O-acylglucuronide Drug Metab. Dispos. 1999, 27 (10) 1143-9 (Pubitemid 29463600)
18. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans Pharm. Res. 1993, 10 (7) 1093-5 (Pubitemid 23211439)
19. Everett, N. B.; Simmons, B.; Lasher, E. P. Distribution of blood (Fe 59) and plasma (I 131) volumes of rats determined by liquid nitrogen freezing Circ. Res. 1956, 4 (4) 419-24
20. Niemi, M.; Backman, J. T.; Fromm, M. F.; Neuvonen, P. J.; Kivisto, K. T. Pharmacokinetic interactions with rifampicin: clinical relevance Clin. Pharmacokinet. 2003, 42 (9) 819-50 (Pubitemid 36995083)
21. Schuetz, E. G.; Schinkel, A. H.; Relling, M. V.; Schuetz, J. D. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans Proc. Natl. Acad. Sci. U.S.A. 1996, 93 (9) 4001-5 (Pubitemid 26144235)
22. Fromm, M. F.; Kauffmann, H. M.; Fritz, P.; Burk, O.; Kroemer, H. K.; Warzok, R. W.; Eichelbaum, M.; Siegmund, W.; Schrenk, D. The effect of rifampin treatment on intestinal expression of human MRP transporters Am. J. Pathol. 2000, 157 (5) 1575-80
23. Lau, Y. Y.; Huang, Y.; Frassetto, L.; Benet, L. Z. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers Clin. Pharmacol. Ther. 2007, 81 (2) 194-204 (Pubitemid 46174816)
24. Thummel, K. E.; Shen, D. D.; Isoherranen, N.; Smith, H. E. Design and Optimization of Dosage Regimens: Pharmacokinetic Data. In The Pharmacological Basis of Therapeutics, 11 th ed.; Gilman, A. G.; Goodman, L. S.; Laurence, L. B.; John, S. L.; Keith, L. P., Eds.; McGraw-Hill Publishing Co.: New York, 2006; pp 1787-888.
25. Fattinger, K.; Cattori, V.; Hagenbuch, B.; Meier, P. J.; Stieger, B. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2 Hepatology 2000, 32 (1) 82-6 (Pubitemid 30432369)
26. Lau, Y. Y.; Okochi, H.; Huang, Y.; Benet, L. Z. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems J. Pharmacol. Exp. Ther. 2006, 316 (2) 762-71 (Pubitemid 43131004)
27. Shitara, Y.; Sugiyama, D.; Kusuhara, H.; Kato, Y.; Abe, T.; Meier, P. J.; Itoh, T.; Sugiyama, Y. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport Pharm. Res. 2002, 19 (2) 147-53 (Pubitemid 34165399)
28. Ueda, K.; Kato, Y.; Komatsu, K.; Sugiyama, Y. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data J. Pharmacol. Exp. Ther. 2001, 297 (3) 1036-43 (Pubitemid 32472501)
29. Kitamura, Y.; Hirouchi, M.; Kusuhara, H.; Schuetz, J. D.; Sugiyama, Y. Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3) J. Pharmacol. Exp. Ther. 2008, 327 (2) 465-73
30. Leonhardt, M.; Keiser, M.; Oswald, S.; Kuhn, J.; Jia, J.; Grube, M.; Kroemer, H. K.; Siegmund, W.; Weitschies, W. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters Drug Metab. Dispos. 2010, 38 (7) 1024-8
31. Ghibellini, G.; Leslie, E. M.; Pollack, G. M.; Brouwer, K. L. Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies Pharm. Res. 2008, 25 (8) 1851-60
32. Swift, B.; Yue, W.; Brouwer, K. L. Evaluation of (99m)technetium- mebrofenin and (99m)technetium-sestamibi as specific probes for hepatic transport protein function in rat and human hepatocytes Pharm. Res. 2010, 27 (9) 1987-98
33. Combes, R. D.; Berridge, T.; Connelly, J.; Eve, M. D.; Garner, R. C.; Toon, S.; Wilcox, P. Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing Eur. J. Pharm. Sci. 2003, 19 (1) 1-11 (Pubitemid 36506932)